Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase

Biochemical Pharmacology

Volumn 52, Issue 11, 1996, Pages 1711-1718

  Phillips, Roger M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

bioreductive drugs; cytotoxicity; DNA interstrand cross links; DT diaphorase; EO9; indoloquinones

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; DICOUMAROL; DNA; EO 1; EO 15; EO 2; EO 4; EO 68; EO 72; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DRUG INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REDUCTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CELL SURVIVAL; DNA; HUMANS; INDOLEQUINONES; INDOLES; KINETICS; NAD(P)H DEHYDROGENASE (QUINONE); STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030582840     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00521-7     Document Type: Article

References (47)

1. 1. Ernster L, DT-diaphorase, a historical review. Chem Scripta 27A: 1-13, 1987.
2. 2. Lind C, Hochstein P and Ernster L, DT-diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 216: 178-185, 1982.
3. 3. Benson AM, Hunkeler MJ and Talalay P, Increase of NAD(P)H:quinone reductase by dietary antioxidants: Possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 77: 5216-5220, 1980.
4. 4. Cadenas E, Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 49: 127-140, 1995.
5. 5. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dyles DJ, Harrison SD and Ross D, Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma - Relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res 52: 4752-4757, 1994.
6. 6. Schlager JJ and Powis G, Cytosolic NAD(P)H:(quinone acceptor) oxidoreductase in human normal and tumour tissue: Effects of cigarette smoking and alcohol. Int J Cancer 45: 403-409, 1990.
7. 7. Smitkamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BFAM and Peters GJ, DT-diaphorase activity in normal and neoplastic human tissues; an indicator of sensitivity to bioreductive agents? Br J Cancer 72: 917-921, 1995.
8. 8. Riley RJ and Workman P, DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43: 1657-1669, 1992.
9. 9. Walton MI, Smith PJ and Workman P, The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9. Cancer Commun 3: 199-206, 1991.
10. 10. Robertson N, Haigh A, Adams GE and Stratford IJ, Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A: 1013-1019, 1994.
11. 11. Smitkamp-Wilms E, Peters GJ, Pinedo HM, van Ark-Otte J and Giaccone G, Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol 47: 1325-1332, 1994.
12. 12. Collard J, Matthew AM, Double JA and Bibby MC, EO9: Relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer 71: 1199-1203, 1995.
13. 13. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD, Reductase enzyme expression across the national cancer institute tumor cell line panel - Correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269, 1996.
14. 14. Workman P and Walton MI, Enzyme directed bioreductive drug development. In: Selective Activation of Drugs by Redox Processes (Eds. Adams GE, Breccia A, Fielden EM and Wardman P), pp. 173-191. Plenum Press, New York, 1990.
15. 15. Hendriks HR, Piazo PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar REC, Fiebig HH, Double JA, Hornstra HW, Pinedo HM, Workman P and Swartsmann G, EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A: 897-906, 1993.
16. 16. Schellens JHM, Planting AST, van Acker BAC, Loos WJ, de Boer-Dennert M, van der Burg MEL, Koier I, Krediet RT, Stoter G and Verweij J, Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 86: 906-912, 1994.
17. 17. Wanders J, Pavlidis N, Gamucci T, ten Bokkel Huinink WW, Dirix L, Wolff I and Verweij J, Phase II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC. Eur J Cancer 31A: 565, 1995.
18. 18. Workman P and Stratford IJ, The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12: 73-82, 1993.
19. 19. Workman P, Binger M and Kooistra KL, Pharmacokinetics, distribution and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys 22: 713-716, 1992.
20. 20. Bibby MC, Cronin BP and Phillips RM, Evaluation of the cytotoxicity of the indoloquinone EO9 in a human colon adenocarcinoma model. Int J Oncol 3: 661-666, 1993.
21. 21. Pizao PE, Peters GJ, Van Ark-Otte J, Smets LA, Smitskamp-Wilms E, Winograd B, Pinedo HM and Giaccone G, Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. Eur J Cancer 29A: 1566-1573, 1993.
22. 22. Matthew AM, Phillips RM and Bibby MC, Optimisation of EO9 activity in human tumour xenografts. Annals Oncol 7 (Suppl. 1): 131, 1996.
23. 23. Gardiner J, Ritchie AA, Cummings J, Jodrell DI and Smyth J, Encapsulation of the indoloquinone EO9 as a potential therapy for the treatment of colorectal liver metastases. Br J Cancer 73 (Suppl. XXVI): 28, 1996.
24. 24. Oostveen EA and Speckamp WN, Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents. Tetrahedron 43: 255-262, 1987.
25. 25. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW and Ross D, Metabolism of bioreductive antitumour compounds by purified rat and human DT-diaphorases. Cancer Res 54: 3196-3201, 1994.
26. 26. Chen HH, Ma JX, Forrest GL, Deng PSK, Martino PA, Lee TD and Chen S, Expression of rat liver NAD(P)H:quinone acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg 177. Biochem J 284: 855-860, 1992.
27. 27. Sharkis DH and Swenson RP, Purification by cibacron blue F3GA dye affinity chromatography and comparison of NAD(P)H:quinone reductase (EC 1.6.99.2) from rat liver cytosol and microsomes. Biochem Biophys Res Commun 161: 434-441, 1989.
28. 28. Bradford MM, A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
29. 29. Henderson PFJ, Statistical analysis of enzyme kinetic data. In: Enzyme Assays: A Practical Approach (Eds. Eisenthal R and Danson MJ), pp. 277-316. IRL Press, Oxford University Press, Oxford, 1993.
30. 30. Hartley JA, Beradinin MD and Souhami RL, An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and second arm cross link reactions. Anal Biochem 193: 131-134, 1991.
31. 31. Lee CS, Hartley JA, Beradini MD, Butler J, Siegel D, Ross D and Gibson NW, Alteration in DNA cross linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase. Biochemistry 31: 3019-3025, 1992.
32. 32. Phillips RM, Hulbert PB, Bibby MC, Sleigh NR and Double JA, In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer 65: 359-364, 1992.
33. 33. Traver RD, Horikoshi T, Dannenberg KD, Stadlbauer THW, Dannenberg PV, Ross D and Gibson NW, NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52: 797-802, 1992.
34. 34. Szmigiero LLC, Erickson RA, Ewig RA and Kohn KW, DNA strand scission and cross linking by diaziridinylbenzoquinone (diaziquone) in human cells and relation to cell killing. Cancer Res 44: 4447-4452, 1984.
35. 35. Siegel D, Gibson NW, Preusch PC and Ross D, Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7293-7300, 1990.
36. 36. Beall HD, Murphy AM, Siegel D, Hargreaves RHJ, Butler J and Ross D, Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumour quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48: 499-504, 1995.
37. 37. Hodnick WF and Sartorelli AC, Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res 53: 4907-4912, 1993.
38. 38. Bligh HFJ, Bartoszek A, Robson CN, Hickson ID, Kasper CB, Beggs JD and Wolf CR, Activation of mitomycin C by NADPH:cytochrome P450 reductase. Cancer Res 50: 7789-7792, 1990.
39. 39. Gustafson DL and Pritsos CA, Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions. Cancer Res 53: 5470-5474, 1993.
40. 40. Bailey SM, Sugget N, Walton MI and Workman P, Structure activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones. Int J Radiat Oncol Biol Phys 22: 649-653, 1992.
41. 41. Maliepaard M, Wolfs A, Groot SE, de Mol NJ and Janssen LHM, Indoloquinone EO9: DNA interstrand cross linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer 71: 836-839, 1995.
42. 42. Walton MI, Sugget N and Workman P, The role of human and rodent DT-diaphorase in the reductive activation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 22: 643-647, 1992.
43. 43. Boland MP, Knox RJ and Roberts JJ, The differences in kinetics of rat and human DT-diaphorase result in differential sensitivity of derived cells to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 41: 867-875, 1991.
44. 44. Spanswick VJ, Butler J, Cummings J and Smyth J, The molecular pharmacology of indoloquinone EO9. Br J Cancer 73 (Suppl. XXVI): 28, 1996.
45. 45. Butler J, Spanswick VJ and Cummings J, The autoxidation of the reduced forms of EO9. Free Rad Res (in press).
46. 46. Plumb JA, Gerritsen M and Workman P, DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 70: 1136-1143, 1994.
47. 47. Bailey SM, Sugget N, Walton MI and Workman P, Bioreductive activation of indoloquinone EO9: Involvement of DT-diaphorase and DNA cross linking. Anal Oncol 3 (Suppl. 1): 185, 1992.